

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Vincent Chau
Application No.: Group No.: N/A
Filed: Herewith Examiner: N/A
For: HUMAN PROTEINS RESPONSIBLE FOR NEDDS ACTIVATION AND
CONJUGATION

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) (5 pages)
- 3.. ☒ Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*


I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a) **37 C.F.R. SECTION 1.10***
- ☐ with sufficient postage as first class mail. ☒ as "Express Mail Post Office to Addressee"
Mailing Label No. EV322209726US

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.


Signature

Date: October 8, 2003

Sean Hunziker
(type or print name of person certifying)

Preliminary Statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.


Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

This application relies, under 35 U.S.C. section 120, on the earlier filing date of prior application Serial No.: 09/216,430, filed on December 18, 1998.

The following references were submitted to, and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application. However, in the event additional copies are necessary, the undersigned will submit such copies upon request.

October 8, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By 
Kerri Pollard Schray
Registration No. 47,066
75 Sidney Street
Cambridge, MA 02139
Telephone – (617) 551-3676
Facsimile – (617) 551-8820

+	
---	--

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Applicati n Number

Filing Date	Herewith
--------------------	-----------------

First Name and Inventor	Chau, Vincent
-------------------------	---------------

Group Art Unit	TBA
----------------	-----

Examiner Name	TBA
---------------	-----

Attorney Docket Number	MPI97-057P1RCP1CN1M
------------------------	---------------------

[illegible][illegible]

**Examiner
Signature**

Date
Considered

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

and Trademark Office, Washington, D.C. 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for us through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Completeness if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	
		Filing Date	Herewith
		First Named Inventor	Chau, Vincent
		Group Art Unit	TBA
		Examiner Name	TBA
		Attorney Docket Number	MPI97-057P1RCP1CN1M
Sheet	1	of	4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C1	Adams, M.D., et al. : Homo Sapiens cDNA Clone Similar to Ubiquitin-Activating Enzyme ; (1997) ; EMBEST Database Entry HSZZ89371, Accession Number AA384235, XP-002103411, See Sequence	
	C2	Altschul et al., Nucleic Acids Research 25(17):3389-3402 (1997)	
	C3	Attwood, et al., Comput. Chem 25(4):329-339 (2001)	
	C4	Chow et al., The Journal of Biological Chemistry 271(19):11339-11346 (1996)	
	C5	Clackson, T. P., Genetically Engineered Monoclonal Antibodies 30(S2):36-39 (1991)	
	C6	Gante J., Agnew chem.. Intro. Ed. Engl. 33:1699-1720 (1994)	
	C7	Hershko, et al., Annu. Rev. Biochem. 61:761-807 (1992)	
	C8	Hillier et al. : Homo Sapiens cDNA Clone Similar to Ubiquitin-Activating Enzyme ; (1997) ; EMBEST Database Entry HS1201636, Accession Number AA401865, XP-002103407, See Sequence	
	C9	Hillier et al. : Homo Sapiens cDNA Clone Similar to Ubiquitin-Activating Enzyme ; (1997) ; EMBEST Database Entry HS1201722, Accession Number AA401968, XP-002103408, See Sequence	
	C10	Horwell D.C., Bioorganic & Med. Chem. 4(10):1573-1576 (1996)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut for form 1449B/PTO		Compl te if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	
		Filing Date	Herewith
		First Nam d Inv nt r	Chau, Vincent
		Group Art Unit	TBA
		Examiner Name	TBA
Sheet	2	of	4
		Attorney Docket Number	MPI97-057P1RCP1CN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C11	Hopkin K., The Journal of NIH Research 9:36-42 (1997)	
	C12	Jentsch, S., Annu. Rev. Genet. 26 :179-207 (1992)	
	C13	Jones et al., Nature 321 :522-525 (1986)	
	C13	Kamitani, T. et al., J. Bio. Chem. 272(22) :14001-14004 (1997)	
	C14	Kamitani, T., et al., J. Bio. Chem. 272(45):28557-28562 (1997)	
	C15	Loeb et al., The Journal of biological Chemistry 267(11):7806-7813 (1992)	
	C16	Kumar et al., Biochemical and Biophysical Research Communication 185(3):1155-1161 (1992)	
	C17	Kumar et al., Biochemical and Biophysical Research Communication 195(1):393-399 (1993)	
	C18	Leyser, et al., Arabidopsis Auxin-Resistance Gene AXR1 Encodes a Protein Related to Ubiquitin-Activatin enzyme E1 364:161-164 (1993)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statem nt: This form is stimat d to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of tim you are required to complete this form should be s nt to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-style: italic;">(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	
				Filing Date	Herewith
				First Named Inventor	Chau, Vincent
				Group Art Unit	TBA
				Examiner Name	TBA
				Attorney Docket Number	MPI97-057P1RCP1CN1M
Sheet	3	of	4		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C19	Liskamp, R.M.J., Recl. Trav. Chim. Pays-Bas 113:1-19 (1994)	
	C20	Marra, M., et al. : Mus Musculus cDNA Clone Similar to Ubiquitin-Conjugating Enzyme E2; (1977) ; EMBEST Database Entry AA671071, Accession Number AA671071, XP-002103412, See Sequence	
	C21	Marx, J. L., Science 229:455-456 (1985)	
	C22	Murray A., Cell 81:149-152 (1995)	
	C23	National Cancer Institute, Cancer Genome Anatomy Project (CGAP) : Homo Sapiens cDNA Clone Similar to Ubiquitin-Conjugating Enzyme E2 ; (1997) ; EMBEST Database Entry HSAA61836, Accession Number AA261836, XP-002103409, See Sequence	
	C24	National Cancer Institute, Cancer Genome Anatomy Project (CGAP) : Homo Sapiens cDNA Clone Similar to Ubiquitin-Conjugating Enzyme E2 ; (1997) ; EMBEST Database Entry HSAA577116, Accession Number AA577116, XP-002103410, See Sequence	
	C25	Osaka et al., Genes & Development 12:2263-2268 (1998)	
	C26	Okura et al., Jnl. Of Immunology:4277-4281 (1996)	
	C27	Ponting, C. P., Brief. Bioinform. 2(1):19-29 (2001)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;"><i>(use as many sheets as necessary)</i></p>				C mplete if Known	
		Applicati n Numb r			
		Filing Date		Herewith	
		First Nam d Inv nt r		Chau, Vincent	
		Group Art Unit		TBA	
		Examiner Name		TBA	
Sheet		4		of 4	
		Attorney Docket Number		MPI97-057P1RCP1CN1M	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C28	Riechmann et al., Nature 332:323-327 (1988)	
	C29	Rock et al., Cell 78:761-771 (1994)	
	C30	Rodwell, J.D., Engineering Monocloncal antibodies 342 :99-100 (1989)	
	C31	Scheffner et al., Cell 75:495-505 (1993)	
	C32	Seebach et al., Helvetica Chimica Acta 75 :913-934 (1992)	
	C33	Thompson et al., CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting, Position-Specific Gap...22(22) :4673-4680 (1994)	
	C34	Townsley et al., Proc. Natl. Acad. Schi. 94 :2362-2367 (1997)	
	C35	Verhoeven et al., Science 239 :1534-1536 (1988)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attach d.

Burden Hour Statem nt: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.